Dean Y. Li - Dec 7, 2021 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Director
Signature
/s/ Nathan Hatfield, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Dec 7, 2021
Transactions value $
-$325,630
Form type
4
Date filed
12/9/2021, 08:21 PM
Previous filing
Dec 9, 2021
Next filing
Jan 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Sale -$305K -14.9K -1.12% $20.44 1.32M Dec 7, 2021 By Dean Y. Li 2021 GRAT F1, F2
transaction RXRX Class A Common Stock Sale -$21.1K -1K -0.08% $21.06 1.32M Dec 7, 2021 By Dean Y. Li 2021 GRAT F1, F3
holding RXRX Class A Common Stock 1.42M Dec 7, 2021 By Dean Li and Ruth Li Revocable Trust
holding RXRX Class A Common Stock 450K Dec 7, 2021 By Dean Y. Li 2021 Family Trust
holding RXRX Class A Common Stock 597K Dec 7, 2021 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person.
F2 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.01 to $20.995 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F3 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $21.03 to $21.11 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.